title: Isolated cutaneous aspergillosis in an acute lymphoblastic leukemia patient after allogeneic stem cell transplantation.
abstract: Cutaneous aspergillosis is very rare and occurs predominantly in immunocompromised patients including transplant recipients. We report a 26-year-old male with acute lymphoblastic leukemia who developed cutaneous aspergillosis after undergoing combined immunosuppressive treatment including corticosteroid, cyclosporine A, mychophenolate mofetil and mesenchymal stem cells for steroid refractory skin acute graft versus host disease after myeloablative haematopoietic stem cell transplantation.  The patient was treated with oral voriconazole therapy and recovered partially.
authors.affiliation: Departments of Infectious Diseases, Faculty of Medicine, Gazi University Ankara, Turkey. oguzel@gazi.edu.tr
authors.forename: Özlem Guzel
authors.initials: ÖG
authors.lastname: Tunçcan
authors.forename: Şahika Zeynep
authors.initials: ŞZ
authors.lastname: Aki
authors.forename: Nalan
authors.initials: N
authors.lastname: Akyürek
authors.forename: Gülsan
authors.initials: G
authors.lastname: Sucak
authors.forename: Esin
authors.initials: E
authors.lastname: Şenol
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage; D001228:Aspergillosis / Q000175:diagnosis* / Q000473:pathology; D003881:Dermatomycoses / Q000175:diagnosis* / Q000473:pathology; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000628:therapy; D011743:Pyrimidines / Q000008:administration & dosage; D033581:Stem Cell Transplantation / Q000009:adverse effects; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole